Biogen's litifilimab shows promising results in treating cutaneous lupus, achieving clear or almost clear skin in patients within one year in a mid-stage study. Phase 3 data for systemic lupus is anticipated by year-end, potentially advancing Biogen's position in the lupus market.
All signs continue to point forward for Biogen’s initial foray into lupus, as litifilimab elicited clear or almost clear skin within one year in patients with cutaneous lupus in a mid-stage study. Data from two Phase 3 studies of systemic lupus are expected by the end of the year.
Original title: “Biogen’s big lupus bet gets boost from new durability data for skin disease”